Pharma & Biotech

The planned acquisition of RAPT Therapeutics by pharmaceutical giant GSK is entering its final stages. As the deal progresses toward...

Investors in Organon & Co. breathed a collective sigh of relief last week. An independent review found no evidence of...

The investment narrative surrounding Iovance Biotherapeutics is shifting. The company has reached a pivotal juncture, moving beyond pure research into...

Investors in Eli Lilly have received two distinct but significant pieces of news this week, highlighting the pharmaceutical giant's growth...

Sangamo Therapeutics has announced a series of strategic moves, including detailed clinical trial data and the initiation of a regulatory...

BioAge Labs is set to engage directly with the investment community at a prominent industry event next week. The biotech...

As FutureTech II Acquisition Corp. progresses toward its planned merger with Longevity Biomedical, a recent change in its independent auditing...

The landscape for clinical-stage biotechnology firms is particularly unforgiving at present, placing companies like IO Biotech at a pivotal crossroads....

Capricor Therapeutics is entering a pivotal period in its quest to secure U.S. approval for a treatment targeting Duchenne muscular...

ImmunityBio has achieved a significant regulatory milestone in Europe, securing conditional marketing authorization from the European Commission for its therapy,...